BioSpace News Archive

Virpax® Pharmaceuticals, Inc., a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central nervous system disorders and anti-viral barrier indications, announced results for a Maximum Tolerated Dose study in Sprague-Dawley Rats for Probudur™.

908 Devices Reports First Quarter 2024 Financial Results and Updates 2024 Revenue Outlook.

Inspire Medical Systems, Inc. announced that its management team will present at the BofA Securities 2024 Health Care Conference on Tuesday, May 14, 2024.

Recce Pharmaceuticals Ltd. (ASX: RCE, FSE: R9Q), (the Company), the Company developing a new class of synthetic anti-infectives, today announced an Independent Safety Committee approved an increase in dosing to 4,000mg over a fast infusion of 30 minutes in a Phase I/II trial evaluating its lead candidate, RECCE® 327 (R327).

X4 Pharmaceuticals, Inc. today announced that it will be reporting financial results for the first quarter ended March 31, 2024 and providing corporate updates on Tuesday, May 7, 2024.

Sutro Biopharma, Inc. today announced that the randomized portion (Part 2) of REFRαME-O1, the registration-directed trial of luveltamab tazevibulin (luvelta) in platinum-resistant ovarian cancer (PROC), is now open for enrollment, and the planned 50 patients in Part 1 of the trial have been enrolled.

Curis, Inc. today announced that the Company will release its first quarter 2024 financial results on Tuesday, May 7, 2024 , at 8:00 a.m. ET.

Forge Biologics Announces Nine Presentations at the American Society of Gene and Cell Therapy (ASGCT) 27th Annual Meeting.

Arsenal Biosciences, Inc. today announced that the first patient has been dosed with AB-2100 in a multi-center, open-label Phase 1/2 clinical trial for patients with clear-cell renal cell carcinoma (ccRCC).

Veru Inc. announced that it has enrolled the first patients in its Phase 2b clinical trial of enobosarm, an oral selective androgen receptor modulator, to avoid muscle loss and to augment fat loss when combined with semaglutide, a Glucagon-like peptide-1 receptor agonist drug, for potentially higher quality weight loss.